Research Analysts Increase SLDB FY2025 Earnings Forecast

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) has recently gained attention as research analysts at Cantor Fitzgerald have revised their FY2025 earnings per share (EPS) estimates for the company. In a report released on Wednesday, February 19th, analyst C. Duncan now predicts that Solid Biosciences is expected to earn ($1.43) per share, a significant improvement from the previous estimate of ($2.45). This update comes amid a broader understanding of the company’s growth potential and current performance metrics.

The consensus expectation for Solid Biosciences’ current full-year earnings stands at ($2.84) per share, highlighting the positive shift in forecasts provided by Cantor Fitzgerald.

Analysts' Ratings and Price Targets

In addition to Cantor Fitzgerald’s revision, several other research analysts have offered their insights on Solid Biosciences. For instance, JPMorgan Chase & Co. recently lowered its price target on the stock from $15.00 to $12.00 but maintained an "overweight" rating. Moreover, Citizens Jmp upgraded their rating to "strong-buy" in early December, showcasing a growing confidence in the company’s prospects.

Another notable report came from Truist Financial, which initiated coverage in January and set a "buy" rating for Solid Biosciences with a price target of $16.00. Additionally, HC Wainwright reiterated a "buy" rating along with a $16.00 price target, reflecting a strong belief in the firm's future success.

As of now, there are nine analysts rating the stock as a buy and four assigning a strong buy rating, indicating a generally favorable outlook. MarketBeat reports a consensus rating of "Buy" with an average price target of around $15.40.

Current Stock Performance

Shares of Solid Biosciences opened at $6.00, which is a noted decline of 7.3%. Over time, the stock has seen a 50-day moving average price of $3.81, while the 200-day moving average price is $5.78. In the last year, shares of Solid Biosciences have fluctuated, hitting a low of $2.88 and a high of $15.05. The company's market cap stands at approximately $243.48 million, with a PE ratio of -1.97.

Insider Activity

Recent insider trading activity also sheds light on current market behavior. COO David T. Howton sold 5,072 shares of the company at an average price of $5.60, totaling nearly $28,403. Following this transaction, Howton retains 15,663 shares, which represent a decrease of 24.46% in ownership. Similarly, another insider, Jessie Hanrahan, sold 4,610 shares for a total value of about $25,816, reflecting a similar trend in insider transactions.

In total, insiders have sold approximately 26,069 shares valued at $137,301 over the past quarter, which now constitutes 13.63% of the company’s stock owned by insiders.

Institutional Investing in Solid Biosciences

In the institutional sphere, recent actions show changes in investments concerning Solid Biosciences. Vestal Point Capital LP raised its position by 5.1% during the third quarter, solidifying its holdings at 2,800,000 shares worth $19,516,000 after acquiring an additional 135,000 shares. Barclays PLC demonstrated a remarkable 412.1% increase in its holdings, now owning 62,856 shares valued at $439,000.

Other firms, including The Manufacturers Life Insurance Company and Point72 Asset Management, also increased their positions in Solid Biosciences, demonstrating positive institutional sentiment with 81.46% of the company’s stock now owned by institutional investors.

Company Overview

Solid Biosciences Inc. is dedicated to developing therapies targeting neuromuscular and cardiac diseases with a strong focus in the United States. The firm's lead product candidate is SGT-003, aimed at treating Duchenne muscular dystrophy, while SGT-501 targets Catecholaminergic polymorphic ventricular tachycardia.

research, forecasts, earnings